fbxo5 Antibody

What is FBXO5 and why is it important in biological research?

FBXO5 (F-box protein 5) functions as an essential subunit of the ubiquitin protein ligase complex and plays crucial roles in regulating tumor occurrence and progression. Recent research has demonstrated that FBXO5 exhibits significant biological effects in cell cycle regulation and immune inflammatory responses. It has been systematically investigated for its potential roles in prognostic assessment and immunological function across multiple cancer types. The protein has become increasingly important in cancer research due to its upregulation in numerous tumor tissues compared to normal tissues, making antibodies against it valuable research tools for understanding oncogenic mechanisms .

What are the primary applications for FBXO5 antibody in laboratory research?

FBXO5 antibody is primarily utilized in several key experimental techniques:

These applications enable researchers to detect FBXO5 protein expression in various cell lines including HEK-293, HeLa, HepG2, K-562, and in tissues such as human ovary, mouse kidney, rat liver, human placenta, and tonsillitis tissue . The antibody has been validated through multiple published studies, with at least 8 publications reporting successful Western Blot applications and 2 publications utilizing it in knockout/knockdown experiments .

How should researchers prepare samples for FBXO5 antibody detection in immunohistochemistry?

For optimal FBXO5 detection in immunohistochemistry:

• Section tissues at appropriate thickness (typically 4-6 μm)

• Perform antigen retrieval using TE buffer at pH 9.0 as the primary recommended method

• Alternatively, citrate buffer at pH 6.0 can be used if TE buffer does not yield satisfactory results

• Use dilution ratios between 1:50-1:500, with specific optimization recommended for each tissue type

• Include proper controls, especially when working with human placenta or tonsillitis tissue, which have shown positive results with FBXO5 antibody

It is essential to titrate the antibody concentration for each specific experimental system to obtain optimal signal-to-noise ratio, as sensitivity can vary between tissue types. Immunohistochemical analyses from the Human Protein Atlas using antibody HPA029048 can serve as reference for expected staining patterns .

What are the optimal storage conditions for maintaining FBXO5 antibody activity?

To maintain optimal activity of FBXO5 antibody:

• Store at -20°C in the recommended storage buffer (PBS with 0.02% sodium azide and 50% glycerol, pH 7.3)

• The antibody remains stable for one year after shipment when properly stored

• For the 10872-1-AP antibody, aliquoting is unnecessary for -20°C storage, simplifying laboratory workflow

• Note that some preparations (20μl sizes) contain 0.1% BSA as a stabilizer

• Avoid repeated freeze-thaw cycles to prevent antibody degradation

Following these storage guidelines ensures consistent performance in experimental applications and maximizes the useful lifespan of the antibody preparation.

What molecular weight forms of FBXO5 should researchers expect to detect with antibodies?

When working with FBXO5 antibodies, researchers should be aware of the following molecular weight specifications:

• The calculated molecular weight of FBXO5 is 54 kDa based on amino acid sequence

• In experimental applications, the observed molecular weights are typically 56 kDa and 45 kDa

• This discrepancy between calculated and observed weights may result from post-translational modifications or alternative splicing

• When performing Western blot, optimizing gel percentage and running conditions is recommended to properly resolve these molecular weight forms

• Verification with positive controls from established cell lines like HeLa or HEK-293 is advisable to confirm antibody specificity

Understanding these expected molecular weight patterns helps researchers accurately interpret Western blot results and identify specific FBXO5 isoforms in their experimental systems.

How can researchers troubleshoot weak or absent FBXO5 signals in Western blot applications?

When encountering weak or absent FBXO5 signals in Western blot:

• Verify antibody dilution - adjust from the recommended 1:500-1:2000 range based on protein abundance

• Increase protein loading amount - FBXO5 expression varies across tissues and may require optimization

• Extend exposure time - longer exposures may be needed for weakly expressed FBXO5

• Improve transfer efficiency - particularly important for the 56 kDa form

• Optimize blocking conditions - excessive blocking can mask epitopes

• Consider cell cycle stage - FBXO5 expression fluctuates during the cell cycle

• Include positive controls from validated sources (HEK-293, HeLa, or HepG2 cells)

Additionally, ensure cell lysates are prepared with proper protease inhibitors to prevent degradation of FBXO5 protein during sample preparation, as this can significantly impact detection sensitivity.

How does FBXO5 expression correlate with cancer prognosis across different tumor types?

FBXO5 expression shows significant prognostic implications across multiple cancer types:

These findings underscore the value of FBXO5 antibodies in prognostic research and potential therapeutic target identification, highlighting the importance of examining FBXO5 expression levels in tumor tissue samples.

What is the relationship between FBXO5 expression and immune cell infiltration in the tumor microenvironment?

FBXO5 expression shows distinct correlations with immune cell infiltration patterns:

• FBXO5 exhibits remarkably positive correlations with regulatory T (Treg) cells and central memory T (Tcm) cells across numerous cancer types

• Significant negative correlations exist between FBXO5 expression and infiltration of natural killer (NK) cells, CD8+ T cells, and T-helper 2 (Th2) cells

• Varied relationships emerge with different T cell subsets - inverse associations with CD4+ Tcm cells, CD4+ effector memory T (Tem) cells, and natural killer T (NKT) cells in most tumors

• Cancer-specific patterns include positive correlation with infiltrating macrophages in prostate adenocarcinoma (PRAD) but negative correlations in glioblastoma (GBM), thyroid carcinoma (THCA), and thymoma (THYM)

• These correlations provide mechanistic insights into how FBXO5 may influence tumor immunity and potential immunotherapeutic responses

Researchers investigating immune components in cancer can utilize FBXO5 antibodies to explore these relationships in experimental models and clinical samples, potentially revealing new immunotherapeutic approaches.

How does FBXO5 expression relate to immunotherapy response biomarkers?

FBXO5 expression shows significant correlations with several immunotherapy response biomarkers:

• FBXO5 demonstrates strong co-expression patterns with immune checkpoint genes across multiple cancer types

• Significant associations exist between FBXO5 expression and tumor mutation burden (TMB) in various cancers, with TMB being a recognized predictor of immunotherapy response

• Microsatellite instability (MSI) status correlates positively with FBXO5 expression in specific cancers including stomach adenocarcinoma (STAD), testicular germ cell tumors (TGCT), and sarcoma (SARC)

• FBXO5 exhibits robust co-expression relationships with genes encoding immune-activating and immunosuppressive factors, particularly in kidney chromophobe (KICH), pancreatic adenocarcinoma (PAAD), uveal melanoma (UVM), liver hepatocellular carcinoma (LIHC), and other cancer types

• Chemokine and chemokine-receptor genes show strong co-expression patterns with FBXO5, further suggesting its role in immune response modulation

These relationships highlight the potential utility of FBXO5 antibodies in studying predictive biomarkers for immunotherapy response, particularly in combinatorial analysis with other immune checkpoint markers.

How can FBXO5 antibodies be utilized in cell cycle and proliferation studies?

FBXO5 antibodies offer valuable applications in cell cycle research:

• Track cell cycle progression - FBXO5's role in the ubiquitin protein ligase complex makes it an important marker for studying cell cycle regulation

• Combine with EdU or BrdU labeling to correlate FBXO5 expression with specific cell cycle phases

• Perform co-immunoprecipitation experiments to identify FBXO5 interaction partners in the ubiquitin-proteasome system

• Use in immunofluorescence microscopy to visualize subcellular localization changes during different cell cycle stages

• Apply in chromatin immunoprecipitation (ChIP) studies to investigate potential associations with replication machinery

These applications can help elucidate the mechanistic role of FBXO5 in cell proliferation control and potentially reveal new therapeutic targets for proliferative disorders including cancer.

What techniques can researchers use to investigate the relationship between FBXO5 and DNA methylation?

To explore FBXO5 and DNA methylation relationships:

• Combine FBXO5 antibody detection with bisulfite sequencing to correlate protein expression with methylation status of its promoter

• Implement chromatin immunoprecipitation followed by sequencing (ChIP-seq) to identify genomic regions where FBXO5 binding may influence methylation patterns

• Use DNA methyltransferase inhibitors (like 5-azacytidine) to examine their effects on FBXO5 expression in cancer cell lines

• Perform methylation-specific PCR (MSP) of the FBXO5 promoter region in conjunction with protein expression analysis

• Apply reduced representation bisulfite sequencing (RRBS) to compare global methylation patterns between high and low FBXO5-expressing tumors

These methodologies can reveal epigenetic mechanisms regulating FBXO5 expression and potentially uncover new therapeutic approaches targeting these regulatory pathways in cancer.

What are the recommended approaches for studying FBXO5 in drug resistance mechanisms?

For investigating FBXO5's role in drug resistance:

• Correlate FBXO5 expression levels with IC50 values of various compounds using data available in the GDSC2 dataset

• Perform knockdown or overexpression of FBXO5 in cancer cell lines followed by drug sensitivity testing

• Combine FBXO5 antibody with markers of drug efflux pumps or DNA repair proteins in co-immunostaining experiments

• Monitor FBXO5 expression changes before and after development of drug resistance in cell line models

• Analyze FBXO5 expression in patient samples before treatment and upon resistance development using immunohistochemistry

• Create stable cell lines with inducible FBXO5 expression to directly examine its impact on drug response

These approaches can identify whether FBXO5 serves as a biomarker for drug sensitivity or resistance, potentially guiding treatment selection for cancer patients.

How should researchers normalize and quantify FBXO5 expression data in comparative studies?

For accurate normalization and quantification of FBXO5 expression:

• For Western blot analysis:

  • Use housekeeping proteins (GAPDH, β-actin, or α-tubulin) consistently across all samples

  • Implement densitometric analysis with software like Image J or similar quantification tools

  • Present data as relative expression normalized to both loading control and reference sample

• For immunohistochemistry quantification:

  • Apply Image-Pro Plus 6.0 or similar software to quantify staining intensity

  • Express FBXO5 protein staining as fold change relative to normal control tissues

  • Perform statistical analysis using unpaired two-tailed Student's t-test to determine significance

• For transcriptomic data:

  • Apply log2 transformation to TPM values (log2(TPM+0.001) or log2(TPM+1))

  • Ensure consistent preprocessing and normalization across all dataset comparisons

  • Use appropriate statistical tests for differential expression analysis

Following these standardized approaches ensures reliable and reproducible quantification of FBXO5 expression across different experimental platforms and sample types.

What control samples are most appropriate for validating FBXO5 antibody specificity?

To properly validate FBXO5 antibody specificity:

• Positive cellular controls:

  • HEK-293 cells, HeLa cells, and HepG2 cells show reliable FBXO5 expression

  • K-562 cells provide additional validation in hematopoietic lineages

  • Human ovary tissue offers a positive tissue control option

• Negative controls:

  • FBXO5 knockout or knockdown samples (siRNA or CRISPR)

  • Peptide competition assays using the immunogenic FBXO5 fusion protein (Ag1296)

  • Secondary antibody-only controls to assess background staining

• Species cross-reactivity:

  • Mouse kidney tissue and rat liver tissue can validate cross-species reactivity

  • Important when translating findings between model systems

Implementing these controls ensures confident interpretation of experimental results and reduces the risk of false positives or negatives in FBXO5 detection assays.

How can researchers address potential discrepancies in FBXO5 antibody results across different experimental platforms?

When encountering discrepancies across experimental platforms:

• Consider isoform specificity:

  • The observed molecular weights of FBXO5 (56 kDa and 45 kDa) may represent different isoforms or post-translational modifications

  • Different antibodies may preferentially detect specific isoforms

• Validate across multiple techniques:

  • Confirm protein expression patterns using orthogonal methods (Western blot, IHC, IF)

  • Correlate protein findings with mRNA expression data when possible

• Antibody validation strategies:

  • Verify results using different FBXO5 antibodies targeting distinct epitopes

  • Include FBXO5 knockout/knockdown controls to confirm specificity

  • Consider using both polyclonal and monoclonal antibodies to compare detection patterns

• Technical optimization:

  • Adjust antigen retrieval methods based on application (TE buffer pH 9.0 or citrate buffer pH 6.0)

  • Optimize antibody dilutions for each specific tissue type and application

  • Titrate antibody concentration in each testing system to obtain optimal results

This systematic approach helps resolve discrepancies and ensures consistent, reliable results across different experimental platforms when working with FBXO5 antibodies.